

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
16 July 2020 (16.07.2020)



(10) International Publication Number
WO 2020/144667 A1

(51) International Patent Classification:

A61K 33/26 (2006.01) A61P 7/06 (2006.01)
A61K 47/36 (2006.01) A61P 9/00 (2006.01)

(21) International Application Number:

PCT/IB2020/051033

(22) International Filing Date:

10 February 2020 (10.02.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

GB1900371.4	10 January 2019 (10.01.2019)	GB
62/803,455	09 February 2019 (09.02.2019)	US
19179820.6	12 June 2019 (12.06.2019)	EP

(71) Applicant: **PHARMACOSMOS HOLDING A/S**
[DK/DK]; Roervangsvej 30, DK-4300 Holbaek (DK).

(72) Inventor; and

(71) Applicant: **OKONKO, Darlington** [GB/GB]; 71 Maryland Road, London, Cambridgeshire CR7 8DJ (GB).


(72) Inventors: **STROM, Claes Christian**; Solvaenget 1, 2960 Rungsted (DK). **CHRISTENSEN, Tobias Sidelmann**; Klostervang 14, 4000 Roskilde (DK). **DINESS, Thomas Goldin**; Rosenvej 16, 2820 Gentofte (DK). **THOMSEN, Lars Lykke**; Skovskellet 47B, 2840 Holte (DK).

(74) Common Representative: **PHARMACOSMOS HOLDING A/S**; Roervangsvej 30, DK-4300 Holbaek (DK).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,

(54) Title: TREATING IRON DEFICIENCY IN SUBJECTS AT RISK OF CARDIOVASCULAR ADVERSE EVENTS AND IRON FOR THE MANAGEMENT OF ATRIAL FIBRILLATION

FIGURE 1



(57) Abstract: The present invention relates to the field of treating iron deficiency with intravenous iron carbohydrate complexes such as iron isomaltoside in subjects at risk of a cardiovascular adverse event, wherein the treatment of iron deficiency reduces the incidence of, or risk for, a cardiovascular adverse event in the subject. In another aspect, the invention provides a method for the reduction of P-wave dispersion/ duration for the management of atrial fibrillation or disorders associated with atrial fibrillation (e.g., heart failure, hypertension, heart valve disease, coronary artery disease, obesity, and diabetes mellitus) in an animal suffering from such a condition which comprises administering to such an animal a therapeutically effective amount of an iron agent via the oral, intramuscular or intravenous route.

[Continued on next page]

WO 2020/144667 A1

CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with information concerning request for restoration of the right of priority in respect of one or more priority claims (Rules 26bis.3 and 48.2(b)(vii))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE